Clinical features and survival outcome of locally advanced extrahepatic cholangiocarcinoma
Çѱ¹°£´ãÃé¿Ü°úÇÐȸÁö 2014³â 18±Ç 1È£ p.1 ~ p.8
ÀÌ»óÀç(Lee Sang-Jae) - Seoul National University College of Medicine Department of Surgery
±Ç¿ìÀÏ(Kwon Woo-Il) - Seoul National University College of Medicine Department of Surgery
°¹ÌÁÖ(Kang Mee-Joo) - Seoul National University College of Medicine Department of Surgery
ÀåÁø¿µ(Jang Jin-Young) - Seoul National University College of Medicine Department of Surgery
À忹¸²(Chang Ye-Rim) - Seoul National University College of Medicine Department of Surgery
Á¤¿ìÇö(Jung Woo-Hyun) - Seoul National University College of Medicine Department of Surgery
±è¼±È¸(Kim Sun-Whe) - Seoul National University College of Medicine Department of Surgery
Abstract
Backgrounds/Aims: Little is known about clinical features and survival outcome in locally advanced unresectable extra-hepatic cholangiocarcinoma (EHC). The aim was to investigate the clinical features and the survival outcome in these patients, and to evaluate the role of palliative resections in locally advanced unresectable EHC.
Methods: Between 1995 and 2007, 280 patients with locally advanced unresectable EHC were identified. Clinical, pathologic, and survival data were investigated. A comparative analysis was done between those who received palliative resection (PR) and those who were not operated on (NR).
Results: The overall median survival of the study population was 10¡¾1 months, and the 3- and 5-year survival rates (YSR) were 8.5% and 2.5%, respectively. The median survival, 3- and 5-YSR of PR were 23 months, 32.1% and 13.1%, respectively. For NR, they were 9 months, 3.9% and 0%, which were significantly worse than PR (p£¼0.001). In univariate analysis, T classification, N classification, tumor location, palliative resection, adjuvant treatment, chemotherapy, and radiation therapy were factors that showed survival difference be-tween PR and NR. Regional lymph node metastasis (RR, 2.084; 95% CI, 1.491-2.914; p£¼0.001), non-resections (RR, 2.270; 95% CI, 1.497-3.443; p£¼0.001), and no chemotherapy (RR, 1.604; 95% CI, 1.095-2.349; p=0.015) were identi-fied as risk factors for poor outcome on multivariate analysis.
Conclusions: Without evidence of systemic disease, pallia-tive resection may provide some survival benefit in selected locally advanced unresectable EHCs and adjuvant treat-ment may further improve survival outcome.
Å°¿öµå
Extrahepatic, Cholangiocarcinoma, Palliative surgery, Survival, Adjuvant therapy
KMID :
0870420140180010001
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)